Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

Trial Profile

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OSTRIA 2; SOLO2; SOLO2/ENGOT-Ov21
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Oct 2017 Results of indirect treatment comparison between olaparib tablets and niraparib tablets from two trial (NOVA and SOLO2), were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 Sep 2017 Results of subgroup analysis presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of analysis of progression free analysis grouped by number of prior lines of platinum based chemotherapy presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top